The drugmaker claims the medication — known as ABBV-CLS-484 — is potentially a “first-in-class” discovery as a “promising new strategy for cancer immunotherapy.” It works in combination with PTPN2/N1, a phosphatase inhibitor, by activating a tumor’s response to interferon — a protein that is part of the body’s natural defense — and stimulating the function of multiple immune cell subsets that have a cascading effect to promote immunity against tumors.
Results of the phase 1 trial were published Oct. 4 in Nature, as a joint research effort including AbbVie experts, the Broad Institute of MIT, Harvard and Calico Life Sciences.
“This is an unprecedented opportunity to evaluate how immune responses work,” said Robert Manguso, PhD, the cosenior author on the study, an associate member at the Broad Institute, an assistant professor at the Massachusetts General Hospital Center for Cancer Research and Harvard Medical School. “The ability to further explore this signaling pathway in clinical studies is really important.”
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
